Filing Flows › Comparisons › SCTX vs TNYA
Scribe Therapeutics vs Tenaya Therapeutics: SCTX and TNYA compared
Scribe Therapeutics is the larger company: $1.9M of revenue in its latest quarter (Q2 2026) against $1.7M for Tenaya Therapeutics (Q3 2026).
Where the money goes: SCTX and TNYA
Scribe Therapeutics (SCTX) · Q2 2026
Scribe Therapeutics, Q2 2026: revenue $1.9M (-61% year over year), operating margin -489.8%, net loss $6.5M. The chart follows the revenue to costs, profit and cash.
Tenaya Therapeutics (TNYA) · Q3 2026
Tenaya Therapeutics, Q3 2026: revenue $1.7M, net loss $18.9M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
| Scribe Therapeutics (SCTX) | Tenaya Therapeutics (TNYA) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $1.9M | $1.7M |
| Revenue growth, Y/Y | -61% | — |
| Operating margin | -489.8% | n/m |
| Net earnings | −$6.5M | −$18.9M |
| Net margin | -337.7% | — |
| Operating cash flow | — | −$17.7M |
Questions
Which is bigger, Scribe Therapeutics or Tenaya Therapeutics?
Scribe Therapeutics is the larger company: $1.9M of revenue in its latest quarter (Q2 2026) against $1.7M for Tenaya Therapeutics (Q3 2026).
More: Scribe Therapeutics earnings · how Scribe Therapeutics makes money · Tenaya Therapeutics earnings · how Tenaya Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Sep 2, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.